Business Information
The company's principal activity is to develop therapeutic products for the treatment of life-threatening diseases. It is in the development stage. The products have initial applications in cardiovascular disease, colorectal cancer, pancreatic cancer, polycystic kidney disease, and drug metabolism. These are based on two distinct core technologies, neugeneo antisense and avicineo cancer vaccine. These compounds have the potential to provide safe and effective treatment for a wide range of human diseases. The company has entered into alliances with supergen, inc, abgenix, inc and exelixis, inc for product development and marketing. It has licensed medtronic, inc to use its antisense compounds in conjunction with medtronic devices.
|
|
Name |
Title
|
Email
|
| Denis Burger | Chmn., CEO | N/A | | Bruce Voss | MD - Lippert, Heilshorn, Associates Inc | Available | | Mark Webber | CFO, CIO | N/A | | Dwight Weller | Dir., Sr. VP - Chemistry, Manufacturing | N/A | | Janet Christensen | VP - Regulatory Affairs, Quality | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 115 | (31,073) | | 2005 | 4,784 | (16,676) | | 2004 | 430 | (24,778)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
